Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma
- 1 September 2013
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the Chinese Medical Association
- Vol. 76 (9), 481-485
- https://doi.org/10.1016/j.jcma.2013.05.007
Abstract
BackgroundAdenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell lung cancer (NSCLC). To date, the efficacious targeted therapy for advanced ASC remains unclear and the epidermal growth factor receptor (EGFR) mutation rate is not well known.MethodsWe retrospectively reviewed clinical information of patients with ASC who were treated with gefitinib or erlotinib at Zhejiang Cancer Hospital between January 2007 and December 2011. Survival analysis was evaluated by the Kaplan-Meier method. EGFR mutations were assessed in part using direct sequencing methods.ResultsIn total, 49 patients with a median age of 57 years were used in this study. Thirteen patients achieved a partial response and 19 had disease stabilization. The objective response rate was 26.5%, and the disease control rate was 65.3%. The median progression-free survival and overall survival were 4.3 and 17.6 months, respectively. In 21 patients with adequate specimens for molecular analysis, 7 (33.3%) had EGFR mutations (4 with deletions within exon 19 and 3 with L858R messenger mutation in exon 21). EGFR mutations were significantly more frequent in women (4/9, 44.4%) than men (3/12, 25%), never-smokers (6/15, 40%), and smokers (1/6, 16.7%).ConclusionEGFR-tyrosine kinase inhibitor (TKI) is an effective treatment for ASC. The frequency of EGFR mutation and clinical characteristics of the EGFR mutants in ASC are similar to those of Asian patients with adenocarcinomaKeywords
This publication has 18 references indexed in Scilit:
- Adenosquamous lung carcinomas: A histologic subtype with poor prognosisLung Cancer, 2011
- Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After LobectomyThe Annals of Thoracic Surgery, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Prognosis and survival after radical resection of primary adenosquamous lung carcinomaEuropean Journal of Cardio-Thoracic Surgery, 2005
- Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lungThe Annals of Thoracic Surgery, 2003
- Lung tumors with mixed histologic pattern. Clinico-pathologic characteristics and prognostic significanceEuropean Journal of Cardio-Thoracic Surgery, 2002
- Do patients with adenosquamous carcinoma of the lung need a more aggressive approach?The Journal of Thoracic and Cardiovascular Surgery, 2001
- A Clinicopathologic Study of Resected Cases of Adenosquamous Carcinoma of the LungChest, 1996